FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2807527954> ?p ?o ?g. }

• W2807527954 endingPage "80" @default.
• W2807527954 startingPage "70" @default.
• W2807527954 abstract "Current & Emerging Pharmaceutical Treatments for Cystic Fibrosis Lung Disease Infection and antibiotics in cystic fibrosisJ Stuart ElbornJ Stuart ElbornJ Stuart Elborn is Professor of Respiratory Medicine and Director of the Centre for Infection and Immunity at Queen’s University Belfast, Northern Ireland. His research interests are the understanding of how infection and inflammation cause lung damage in cystic fibrosis and bronchiectasis. He is currently President of the European Cystic Fibrosis Society.Search for more papers by this authorPublished Online:27 Jun 2013https://doi.org/10.2217/ebo.12.525AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack Citations ShareShare onFacebookTwitterLinkedInReddit View chapterAbstract: Infection of the airways is the key driver of progressive lung damage in cystic fibrosis (CF). Intermittent infection occurs in early life and can be managed with eradication strategies using oral and inhaled antibiotics. By the third decade, most people with CF have chronic infection, usually with Pseudomonas aeruginosa. Chronic suppressive antimicrobial therapy improves lung function, reduces exacerbation frequency and improves survival. Optimal treatment of infection in CF is a key part of the delivery of optimal care in this disease. References1 Wainwright CE , Vidman R , Armstrong DS et al. ; ACFBAL Study Investigators. Effect of bronchoalveolar lavage-directed therapy on Pseudomonas aeruginosa infection and structural lung injury in children with cystic fibrosis: a randomized trial . JAMA 306 (2) , 163 – 171 (2011) . Crossref, Medline, CAS, Google Scholar2 Smyth A , Elborn JS . Exacerbations in cystic fibrosis: 3- management . Thorax 63 , 180 – 184 (2008) . Crossref, Medline, CAS, Google Scholar3 Aaron SD , Vandemheen KL , Ramotar K et al. Infection with transmissible strains of Pseudomonas aeruginosa and clinical outcomes in adults with cystic fibrosis . JAMA 304 (19) , 2145 – 2153 (2010) . Crossref, Medline, CAS, Google Scholar4 UK CF Registry. Annual Data Report 2010. UK Cystic Fibrosis Trust, Bromley, UK (2012) . Google Scholar5 Tunney MM , Klem ER , Fodor AA et al. Use of culture and molecular analysis to determine the effects of antibiotic treatment on microbial community diversity and abundance during exacerbation in patients with cystic fibrosis . Thorax 66 (7) , 579 – 584 (2011) . Crossref, Medline, CAS, Google Scholar6 Tunney MM , Field TR , Moriarty TF et al. Detection of anaerobic bacteria in high numbers in sputum from patients with cystic fibrosis . Am. J. Respir. Crit. Care Med. 177 , 995 – 1001 (2008) . Crossref, Medline, Google Scholar7 Ramsey BW , Pepe MS , Quan JM et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group . N. Engl. J. Med. 340 , 23 – 30 (1999) . Crossref, Medline, CAS, Google Scholar8 The UK Cystic Fibrosis Trust Microbiology Laboratory Standards Working Group. Report of the UK Cystic Fibrosis Trust Microbiology Laboratory Standards Working Group. UK Cystic Fibrosis Trust, Bromley, Kent (2010) . Google Scholar9 Foweraker JE , Laughton CR , Brown DF , Bilton D . Comparison of methods to test antibiotic combinations against heterogenous populations of multiresistant Pseudomonas aeruginosa from patients with acute infective exacerbations in cystic fibrosis . Antimicrob. Agents Chemother. 53 , 4809 – 4815 (2009) . Crossref, Medline, CAS, Google Scholar10 Symth AR , Walters S . Prophylactic anti-staphylococcus antibiotics for cystic fibrosis . Cochrane Database Syst. Rev. 12 , CD001912 (2012) . Medline, Google Scholar11 Dasenbrook EC , Checkley W , Merlo CA , Konstan MW , Lechtzin N , Boyle MP . Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis . JAMA 303 , 2386 – 2392 (2010) . Crossref, Medline, CAS, Google Scholar12 Hansen CR , Pressler T , Höiby N . Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience . J. Cyst. Fibros. 7 , 523 – 530 (2008) . Crossref, Medline, CAS, Google Scholar13 Ratjen F , Doering G , Nikolaizik WH . Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonization in patients with cystic fibrosis . Lancet 358 , 983 – 984 (2001) . Crossref, Medline, CAS, Google Scholar14 Olivier KN , Weber DJ , Lee JH et al. Nontuberculous mycobacteria . Am. J. Respir. Crit. Care Med. 167 , 835 – 840 (2003) . Crossref, Medline, Google Scholar15 Littlewood JM , Kock C , Lambert PA et al. A ten year review of colomycin . Respir. Med. 97 (7) , 632 – 640 (2000) . Crossref, Google Scholar16 Flume PA , O’Sullivan BP , Robinson KA et al. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health . Am. J. Respir. Crit. Care Med. 176 , 957 – 969 (2007) . Crossref, Medline, CAS, Google Scholar17 Parkins MD , Elborn JS . Tobramycin inhalation powder™: a novel drug delivery system for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis . Expert Rev. Respir. Med. 5 (5) , 609 – 622 (2011) . Crossref, Medline, CAS, Google Scholar18 Parkins MD , Elborn JS . Aztreonam lysine: a novel inhalational antibiotic for cystic fibrosis . Expert Rev. Respir. Med. 4 (4) , 435 – 444 (2010) . Crossref, Medline, CAS, Google Scholar19 Saiman L . Infection prevention and control in cystic fibrosis . Curr. Opin. Infect. Dis. 24 (4) , 390 – 395 (2011) . Crossref, Medline, Google ScholarWebsites101 Antibiotic treatment for cystic fibrosis. Report of the UK Cystic Fibrosis Trust Antibiotic Working Group (third edition). www.cysticfibrosis.org.uk/media/82010/CD_Antibiotic_treatment_for_CF_May_09.pdf Google Scholar102 Standards for the clinical care of children and adults with cystic fibrosis (second edition) (2011). www.cysticfibrosis.org.uk/media/82070/CD_Standards_of_care_Dec_11.pdf Google ScholarFiguresReferencesRelatedDetails Current & Emerging Pharmaceutical Treatments for Cystic Fibrosis Lung DiseaseMetrics Downloaded 17 times History Published online 27 June 2013 Published in print June 2013 Information© Future Medicine Ltd© Future Medicine LtdPDF download" @default.
• W2807527954 created "2018-06-13" @default.
• W2807527954 creator A5039017673 @default.
• W2807527954 date "2013-06-01" @default.
• W2807527954 modified "2023-09-25" @default.
• W2807527954 title "Infection and antibiotics in cystic fibrosis" @default.
• W2807527954 cites W1983262214 @default.
• W2807527954 cites W2033168765 @default.
• W2807527954 cites W2033172874 @default.
• W2807527954 cites W2054027186 @default.
• W2807527954 cites W2066510676 @default.
• W2807527954 cites W2076782896 @default.
• W2807527954 cites W2079457968 @default.
• W2807527954 cites W2089590453 @default.
• W2807527954 cites W2101667079 @default.
• W2807527954 cites W2113238658 @default.
• W2807527954 cites W2124135806 @default.
• W2807527954 cites W2126192952 @default.
• W2807527954 cites W2142648608 @default.
• W2807527954 cites W2317332612 @default.
• W2807527954 cites W2332371048 @default.
• W2807527954 cites W4238818129 @default.
• W2807527954 cites W4375175834 @default.
• W2807527954 doi "https://doi.org/10.2217/ebo.12.525" @default.
• W2807527954 hasPublicationYear "2013" @default.
• W2807527954 type Work @default.
• W2807527954 sameAs 2807527954 @default.
• W2807527954 citedByCount "0" @default.
• W2807527954 crossrefType "other" @default.
• W2807527954 hasAuthorship W2807527954A5039017673 @default.
• W2807527954 hasConcept C126322002 @default.
• W2807527954 hasConcept C177713679 @default.
• W2807527954 hasConcept C203014093 @default.
• W2807527954 hasConcept C2775832221 @default.
• W2807527954 hasConcept C2776938444 @default.
• W2807527954 hasConcept C2777014857 @default.
• W2807527954 hasConcept C2777637488 @default.
• W2807527954 hasConcept C2777714996 @default.
• W2807527954 hasConcept C2778974779 @default.
• W2807527954 hasConcept C2779379686 @default.
• W2807527954 hasConcept C501593827 @default.
• W2807527954 hasConcept C523546767 @default.
• W2807527954 hasConcept C54355233 @default.
• W2807527954 hasConcept C71924100 @default.
• W2807527954 hasConcept C86803240 @default.
• W2807527954 hasConcept C89423630 @default.
• W2807527954 hasConceptScore W2807527954C126322002 @default.
• W2807527954 hasConceptScore W2807527954C177713679 @default.
• W2807527954 hasConceptScore W2807527954C203014093 @default.
• W2807527954 hasConceptScore W2807527954C2775832221 @default.
• W2807527954 hasConceptScore W2807527954C2776938444 @default.
• W2807527954 hasConceptScore W2807527954C2777014857 @default.
• W2807527954 hasConceptScore W2807527954C2777637488 @default.
• W2807527954 hasConceptScore W2807527954C2777714996 @default.
• W2807527954 hasConceptScore W2807527954C2778974779 @default.
• W2807527954 hasConceptScore W2807527954C2779379686 @default.
• W2807527954 hasConceptScore W2807527954C501593827 @default.
• W2807527954 hasConceptScore W2807527954C523546767 @default.
• W2807527954 hasConceptScore W2807527954C54355233 @default.
• W2807527954 hasConceptScore W2807527954C71924100 @default.
• W2807527954 hasConceptScore W2807527954C86803240 @default.
• W2807527954 hasConceptScore W2807527954C89423630 @default.
• W2807527954 hasLocation W28075279541 @default.
• W2807527954 hasOpenAccess W2807527954 @default.
• W2807527954 hasPrimaryLocation W28075279541 @default.
• W2807527954 hasRelatedWork W1990069335 @default.
• W2807527954 hasRelatedWork W2008210155 @default.
• W2807527954 hasRelatedWork W2110977151 @default.
• W2807527954 hasRelatedWork W2157195518 @default.
• W2807527954 hasRelatedWork W2160909416 @default.
• W2807527954 hasRelatedWork W2497383981 @default.
• W2807527954 hasRelatedWork W2996804620 @default.
• W2807527954 hasRelatedWork W3123420543 @default.
• W2807527954 hasRelatedWork W4214652093 @default.
• W2807527954 hasRelatedWork W4246222824 @default.
• W2807527954 isParatext "false" @default.
• W2807527954 isRetracted "false" @default.
• W2807527954 magId "2807527954" @default.
• W2807527954 workType "other" @default.